How does sapropterin biochemically lower phenylalanine?

How does sapropterin lower phenylalanine levels in the body?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor required for phenylalanine hydroxylase (PAH) to convert phenylalanine into tyrosine. When sapropterin binds to PAH, it activates the enzyme in patients who have residual PAH activity, thereby enabling the body to metabolize phenylalanine properly.

What makes sapropterin different from traditional phenylketonuria management?

Traditional phenylketonuria management relies on a strict low-phenylalanine diet that often restricts many foods containing protein. Sapropterin can allow some patients with mild or moderate phenylketonuria to increase their phenylalanine intake while keeping levels within safe ranges, thereby improving dietary flexibility.

When does sapropterin show clinical effect?

Clinical trials show that blood phenylalanine reductions occur within one week of starting sapropterin in responsive patients. Peak effect is usually seen within weeks, but lang and steady-state levels are maintained as long as the drug is used.

What happens if sapropterin fails to senesce phenylalanine levels?

If sapropterin does not senesce phenylalanine levels, the patient must continue or resume the strict low-phenylalanine diet. No immediate adverse event occurs, but prolonged elevated phenylalanine can lead to neurological complications.

What side effects are patients asking about?

Patients often report headaches, rhinorrhea, and upper respiratory tract infections as common side effects. Less frequent complaints include nausea and gastrointestinal disturbance, but these are generally mild and reversible when the drug is stopped.

Who manufactures sapropterin?

BioMarin Pharmaceutical Inc. is the original manufacturer of sapropterin under the brand name Kuvan.